Billiontoone (NASDAQ:BLLN) Insider Sells $287,363.04 in Stock

Billiontoone, Inc. (NASDAQ:BLLN) insider Bosch John Roderick Ten sold 2,832 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $101.47, for a total value of $287,363.04. Following the completion of the transaction, the insider directly owned 34,968 shares in the company, valued at $3,548,202.96. This trade represents a 7.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Billiontoone Stock Performance

Shares of BLLN opened at $105.15 on Friday. The company has a market cap of $4.84 billion and a price-to-earnings ratio of 191.18. The business’s fifty day simple moving average is $89.82 and its two-hundred day simple moving average is $87.35. Billiontoone, Inc. has a 12 month low of $61.96 and a 12 month high of $138.70. The company has a current ratio of 10.92, a quick ratio of 10.58 and a debt-to-equity ratio of 0.18.

Billiontoone (NASDAQ:BLLN) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.34 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.33. The business had revenue of $108.39 million during the quarter, compared to analysts’ expectations of $95.81 million. The firm’s revenue for the quarter was up 83.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.39) EPS. Research analysts anticipate that Billiontoone, Inc. will post 0.93 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Adams Street Partners LLC bought a new stake in shares of Billiontoone during the 4th quarter valued at about $140,063,000. Baillie Gifford & Co. bought a new position in shares of Billiontoone in the 4th quarter worth approximately $103,786,000. Price T Rowe Associates Inc. MD purchased a new position in shares of Billiontoone in the fourth quarter worth approximately $39,717,000. JPMorgan Chase & Co. bought a new stake in Billiontoone during the fourth quarter valued at approximately $32,078,000. Finally, Wasatch Advisors LP bought a new stake in Billiontoone during the first quarter valued at approximately $29,179,000.

Analysts Set New Price Targets

BLLN has been the topic of several research analyst reports. Weiss Ratings cut shares of Billiontoone from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, June 5th. JPMorgan Chase & Co. lifted their price target on shares of Billiontoone from $120.00 to $125.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. BTIG Research decreased their price objective on shares of Billiontoone from $140.00 to $130.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Wells Fargo & Company lowered their price objective on shares of Billiontoone from $110.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Thursday, March 5th. Finally, Guggenheim raised their target price on shares of Billiontoone from $100.00 to $120.00 and gave the stock a “buy” rating in a report on Wednesday, May 13th. Six equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $125.29.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.